Navidea Biopharmaceuticals to Announce Fourth Quarter and Full-Year 2013 Financial Results on Thursday, March 6, 2014
March 03 2014 - 2:18PM
Business Wire
– Webcast and conference call with
investment community at 8:30 a.m. ET –
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a
biopharmaceutical company focused on precision diagnostic
radiopharmaceuticals, today announced that the Company will report
its financial results for the fourth quarter and full-year 2013, on
Thursday, March 6, 2014 before the market opens. Company management
will host a conference call and slide presentation via webcast,
also on March 6, 2014, at 8:30 a.m. ET to discuss results and
corporate developments.
Investors and the public are invited to access the live webcast
through the link below. Participants who would like to ask
questions during the question and answer session following the
presentation must participate by telephone also. Participants are
encouraged to log-in and/or dial-in fifteen minutes before the
conference call begins. The webcast replay is expected to be
available on our investor website, http://ir.navidea.com,
approximately two to four hours after the live event.
Event: Navidea Biopharmaceuticals Q4 2013 and
Full-Year Financial Results Conference Call Date/Time: Thursday,
March 6, 2014 at 8:30 a.m. ET Webcast Link:
http://www.media-server.com/m/p/dh2x4bbc
Dial-in Number – US: 1 (800) 708-4539 Dial in Number – Int’l: 1
(847) 619-6396 Participant Passcode: 36792037 Replay
A webcast replay will be available on the
Investor Relations section of our website at
http://ir.navidea.com
About Navidea Biopharmaceuticals Inc.
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a
biopharmaceutical company focused on the development and
commercialization of precision diagnostics and radiopharmaceutical
agents. Navidea is developing multiple precision diagnostic
products and platforms including NAV4694, NAV5001, Manocept™ and
NAV1800 (RIGScan™), to help identify the sites and pathways of
undetected disease and enable better diagnostic accuracy, clinical
decision-making and, ultimately, patient care. Lymphoseek®
(technetium 99m tilmanocept) Injection, Navidea’s first commercial
product from the Manocept platform, was approved by the FDA in
March 2013. Navidea’s strategy is to deliver superior growth and
shareholder return by bringing to market novel radiopharmaceutical
agents and advancing the Company’s pipeline through selective
acquisitions, global partnering and commercialization efforts. For
more information, please visit www.navidea.com.
Navidea BiopharmaceuticalsBrent Larson, 614-822-2330Executive VP
& CFOorSharon Correia, 978-655-2686Associate Director,
Corporate Communications
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Sep 2023 to Sep 2024